Loading...
Please wait, while we are loading the content...
Similar Documents
Alterations in the Plasma Proteome Induced by SARS-CoV-2 and MERS-CoV Reveal Biomarkers for Disease Outcomes for COVID-19 Patients.
| Content Provider | Europe PMC |
|---|---|
| Author | Alaiya, Ayodele Alshukairi, Abeer Shinwari, Zakia AL-Fares, Mariam Alotaibi, Jawaher AlOmaim, Waleed Alsharif, Ibtihaj Bakheet, Razan Alharbi, Layla Allam, Rabab Asiri, Ayed Memish, Ziad Alromaih, Khaldoun Al-Mozaini, Maha |
| Copyright Year | 2021 |
| Abstract | PurposeThis study aimed to understand the pathophysiology of host responses to infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/(COVID-19) and Middle East respiratory syndrome coronavirus (MERS-CoV) and to identify proteins for patient stratification with different grades of illness severity.Patients and MethodsPeripheral blood samples from 43 patients with different grades of COVID-19, 7 MERS-CoV patients admitted to the ICU, and 10 healthy subjects were analyzed using label-free quantitative liquid chromatography–mass spectrometry (LC–MS).ResultsWe identified 193 and 91 proteins that differed significantly between COVID-19 and MERS-CoV sample groups, respectively, and 49 overlapped between datasets. Only 10 proteins are diagnostic of asymptomatic cases, 12 are prognostic of recovery from severe illness, and 28 are prognostic of a fatal outcome of COVID-19. These proteins are implicated in virus-specific/related signaling networks. Notable among the top canonical pathways are humoral immunity, inflammation, acute-phase response signaling, liver X receptor/retinoid X receptor (LXR/RXR) activation, coagulation, and the complement system. Furthermore, we confirmed positive viral shedding in 11.76% of 51 additional peripheral blood samples, indicating that caution should be taken to avoid the possible risk of transfusion of infected blood products.ConclusionWe identified COVID-19 and MERS-CoV protein panels that have potential as biomarkers and might assist in the prognosis of SARS-CoV-2 infection. The identified markers further our understanding of COVID-19 disease pathophysiology and may have prognostic or therapeutic potential in predicting or managing host cell responses to human COVID-19 and MERS-CoV infections. |
| Page Count | 16 |
| Journal | Journal of Inflammation Research |
| Volume Number | 14 |
| PubMed Central reference number | PMC8421783 |
| PubMed reference number | 34511970 |
| e-ISSN | 11787031 |
| DOI | 10.2147/JIR.S322430 |
| Language | English |
| Publisher | Dove |
| Publisher Date | 2021-09-01 |
| Access Restriction | Open |
| Rights License | This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). © 2021 Alaiya et al. |
| Subject Keyword | COVID-19 SARS-CoV MERS-CoV expression proteomics biomarkers |
| Content Type | Text |
| Resource Type | Article |
| Subject | Immunology Immunology and Allergy |
